ReviewJMA journal2026
Targeting Exportin-1 in Cancer: From Nuclear Export to Oncogenic Transcriptional Hubs.
Review in JMA journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Maintaining cellular homeostasis requires precise coordination of molecular trafficking between the nucleus and the cytoplasm. Central to this process is the nucleocytoplasmic transport system, which governs the spatial distribution of proteins and RNA. Exportin-1 (XPO1), also known as chromosome region maintenance 1 (CRM1), is the principal nuclear export receptor responsible for the transport of hundreds of cargo proteins bearing leucine-rich nuclear export signals. In a wide range of malignancies, XPO1 is frequently dysregulated through overexpression or recurrent somatic mutations. This dysregulation results in inappropriate cytoplasmic sequestration of tumor suppressor proteins and other regulatory factors, thereby facilitating oncogenic signaling and malignant transformation. Cancer cells consequently become highly dependent on XPO1-mediated nuclear export, positioning XPO1 as a rational therapeutic target. Consistent with this concept, selective inhibitors of nuclear export, such as selinexor, have demonstrated clinical efficacy, received regulatory approval for the treatment of multiple myeloma and diffuse large B-cell lymphoma, and are currently being evaluated in clinical trials for solid tumors. Beyond the canonical transport function, accumulating evidence indicates that XPO1 performs noncanonical roles as a chromatin-associated scaffold that supports the assembly of oncogenic transcriptional hubs and phase-separated biomolecular condensates. These structures integrate nuclear transport machinery with transcriptional regulatory complexes to drive aberrant gene expression programs, particularly in leukemias harboring
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.